Idioma:

Outcome Following Infliximab Therapy in Children With Ulcerative Colitis

HYAMS, Jeffrey S ; LERER, Trudy ; ROSH, Joel ; GROSSMAN, Andrew ; TOMER, Gitit ; KAY, Marsha ; CRANDALL, Wallace ; OLIVA-HEMKER, Maria ; KELJO, David ; LELEIKO, Neal ; MARKOWITZ, James ; GRIFFITHS, Anne ; PFEFFERKORN, Marian ; STEPHENS, Michael ; EVANS, Jonathan ; OTLEY, Anthony ; CARVALHO, Ryan ; MACK, David ; BOUSVAROS, Athos

The American journal of gastroenterology, 2010-06, Vol.105 (6), p.1430-1436 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Sem texto completo

Citações Citado por

Enviar para

Título:
Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
Autor: HYAMS, Jeffrey S ; LERER, Trudy ; ROSH, Joel ; GROSSMAN, Andrew ; TOMER, Gitit ; KAY, Marsha ; CRANDALL, Wallace ; OLIVA-HEMKER, Maria ; KELJO, David ; LELEIKO, Neal ; MARKOWITZ, James ; GRIFFITHS, Anne ; PFEFFERKORN, Marian ; STEPHENS, Michael ; EVANS, Jonathan ; OTLEY, Anthony ; CARVALHO, Ryan ; MACK, David ; BOUSVAROS, Athos
Assuntos: Adolescent ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Child ; Cohort Studies ; Colitis, Ulcerative - drug therapy ; Female ; Gastroenterology ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunomodulators ; Infliximab ; Male ; Medical sciences ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Prospective Studies ; Registries ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Treatment Outcome
É parte de: The American journal of gastroenterology, 2010-06, Vol.105 (6), p.1430-1436
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Infliximab is effective in treating moderate/severe ulcerative colitis (UC) in adults. The aim of this study was to determine the outcome after treatment with infliximab in pediatric UC. We performed a multicenter cohort study of 332 pediatric patients with UC enrolled in the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry. Children12 months). Mean age at infliximab initiation was 13.3+/-2.6 (range 6-17) years; 87% of patients had pancolitis. Median follow-up was 30 months. Continuous maintenance (CM) therapy was given in 65%, episodic in 21%, episodic converted to CM in 6%, and insufficient data in 8% of patients. Sixty-three percent of patients were corticosteroid refractory, and 35% were corticosteroid dependent. Concomitant medications at first infliximab infusion included corticosteroids (87%), thiopurines (63%), and 5-aminosalicylates (51%). Corticosteroid-free inactive disease by physician global assessment was noted in 12/44 (27%), 15/39 (38%), and 6/28 (21%) patients at 6, 12, and 24 months, respectively. Kaplan-Meier analysis showed that the likelihood of remaining colectomy free after treatment with infliximab was 75% at 6 months, 72% at 12 months, and 61% at 2 years. In this cohort of children with UC receiving infliximab, corticosteroid-free inactive disease was observed in 38 and 21% of patients at 12 and 24 months, respectively. By 24 months, 61% of patients had avoided colectomy.
Editor: Basingstoke: Nature Publishing Group
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Outcome Following Infliximab Therapy in Children With Ulcerative Colitis

Basingstoke: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.